Z-Leu-Leu-Nle-aldehyde
Modify Date: 2025-08-23 10:48:54
Z-Leu-Leu-Nle-aldehyde structure
|
Common Name | Z-Leu-Leu-Nle-aldehyde | ||
|---|---|---|---|---|
| CAS Number | 133407-83-7 | Molecular Weight | 475.62100 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C26H41N3O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Z-Leu-Leu-Nle-aldehydeZ-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a γ-secretase inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia[1][2]. |
| Name | benzyl N-[4-methyl-1-[[4-methyl-1-oxo-1-(1-oxohexan-2-ylamino)pentan-2-yl]amino]-1-oxopentan-2-yl]carbamate |
|---|---|
| Synonym | More Synonyms |
| Description | Z-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a γ-secretase inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Z-LLNle-CHO (0-5 µM or 0-3 µM; 72 h) results in a dose-dependent decrease in cell viability/proliferation in six breast cancer cell lines[1]. Z-LLNle-CHO shows proteasome inhibitory activity, which contributes to cytotoxicity to MCF-7 cells[1]. Z-LLNle-CHO blocks Akt-mediated pro-survival pathways and induces caspase- and ROS-dependent cell apoptosis in Nalm6 and 697 cells[2]. Cell Viability Assay[1] Cell Line: MCF-7, BT474, T47D, MDA-MB-231, SKBR3, and MDA-MB-468 cells Concentration: 0-5 µM (for MCF-7); 0-3 µM Incubation Time: 72 h Result: Inhibited MCF-7, BT474, T47D, MDA-MB-231, SKBR3, and MDA-MB-468 cells with ED50 values of 3.25, 2.5, 2.4, 1.8, 1.6, and 1.4 μM, respectively. Apoptosis Analysis[2] Cell Line: Precursor-B ALL cells Concentration: 0-2.5 µM Incubation Time: 18-24 h Result: Induced cell apoptosis. |
| In Vivo | Z-LLNle-CHO (5 mg/kg; s.c.; single daily for 12 days) inhibits engraftment of B-lymphoblasts in precursor-B ALL xenograft model[2]. Animal Model: Female SCID/NOD mice (6-8-week-old; precursor-B ALL xenograft model)[2]. Dosage: 5 mg/kg Administration: Subcutaneous injection; single daily for 12 days Result: Delayed or prevented engraftment of B-lymphoblasts in 50% of the animals comprising the experimental group. |
| Molecular Formula | C26H41N3O5 |
|---|---|
| Molecular Weight | 475.62100 |
| Exact Mass | 475.30500 |
| PSA | 113.60000 |
| LogP | 4.90500 |
| InChIKey | RNPDUXVFGTULLP-UHFFFAOYSA-N |
| SMILES | CCCCC(C=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)OCc1ccccc1 |
| WGK Germany | 3 |
|---|
| Z-Leu-Leu-Nle-H |
| benzyl N-[(2S)-4-methyl-1-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxohexan-2-yl]amino]pentan-2-yl]amino]-1-oxopentan-2-yl]carbamate |
| IN1097 |
| Z*Leu-Leu-Nle-CHO |
| Z-Leu-Leu-Nle-aldehyde |